News | Pharmaceuticals | November 15, 2018

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes

Fewer MACE events observed with Farxiga vs. placebo in DECLARE-TIMI 58 Trial, but finding did not reach statistical significance

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes

November 15, 2018 — AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin) as a late-breaking abstract at the American Heart Association (AHA) Scientific Sessions 2018, Nov. 10-12 in Chicago. Results were simultaneously published in the New England Journal of Medicine (NEJM).1

DECLARE-TIMI 58 is the largest SGLT-2 inhibitor (SGLT-2i) CVOT conducted to date, including more than 17,000 patients across 33 countries. Results showed that Farxiga significantly reduced the risk of hospitalization for heart failure (hHF) or CV death composite vs. placebo by 17 percent (4.9 percent vs. 5.8 percent; HR 0.83 [95 percent CI 0.73-0.95], p=0.005), one of the two primary efficacy endpoints. The reduction in hHF or CV death was consistent across the entire patient population, which included those with CV risk factors and those with established CV disease.1 Farxiga is not indicated to reduce the risk of CV events or hHF.

Additionally, there were fewer major adverse cardiovascular events (MACE) observed with Farxiga for the other primary efficacy endpoint, however this did not reach statistical significance (8.8 percent for Farxiga vs. 9.4 percent for placebo; HR 0.93 [95 percent CI 0.84-1.03], p=0.17).1

DECLARE-TIMI 58 also confirmed the safety profile for Farxiga, which met the primary safety endpoint of non-inferiority vs. placebo, demonstrating no increase in the composite of MACE, defined as CV death, heart attack or stroke.1

On other relevant safety measures, the trial showed no imbalance with Farxiga vs. placebo in amputations (1.4 percent vs. 1.3 percent), fractures (5.3 percent vs. 5.1 percent), bladder cancer (0.3 percent vs. 0.5 percent) or Fournier’s gangrene (1 case vs. 5 cases). The respective incidences of diabetic ketoacidosis (0.3 percent vs. 0.1 percent) and genital infections (0.9 percent vs. 0.1 percent) were rare.1

Although secondary endpoints were only nominally significant, the renal composite endpoint showed that Farxiga reduced the rate of new or worsening nephropathy by 24 percent vs. placebo across the broad patient population studied (4.3 percent vs. 5.6 percent; HR 0.76 [95 percent CI 0.67-0.87]), and there were fewer all-cause mortality events with Farxiga vs. placebo (6.2 percent vs. 6.6 percent; HR 0.93 [95 percent CI 0.82-1.04]).1

Farxiga is not indicated to reduce the risk of HF, other CV outcomes, nephropathy or all-cause mortality.

For more information: www.nejm.org

Reference

1. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, Nov. 10, 2018. DOI: 10.1056/NEJMoa1812389

Related Content

The startup company Genetesis introduced a new cardiac imaging modalityit calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle. This was at AHA.18, AHA 2018 - the American Heart Association annual meeting

The startup company Genetesis introduced a new cardiac imaging modality it calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle.

Feature | AHA | January 14, 2019 | Dave Fornell, Editor
Here are a few of the takeaways from the clinical studies presented and new technology shown on the exhibit floor at
Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance. #AHA18

The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s (AHA) 2018 Scientific Sessions this week. Chicago. It provides evidence-based recommendations for youth ages three through 17 and adults to safely get the physical activity and was a major topic of discussion. Pictured here is Russel Pate, Ph.D., Univerity Of South Carolina, chair of the National Physical Activity Plan Alliance, presenting on the main stage at AHA, with details relat d to the new guidelines.

Feature | AHA | November 20, 2018
November 7, 2018 — Here is a list of some of the key clinical trial presentations at the 2018...
Videos | AHA | November 19, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technologies on display on th
Overlay Init